Can Viking Therapeutics Hold Its Edge as Obesity Rivalry Heats Up?

Key Takeaways Viking is advancing VK2735 in oral and subcutaneous forms to treat obesity.Pfizer's $4.9B Metsera buy will add four obesity drug programs to its pipeline.Mixed trial results for VKTX's oral VK2735 shift focus to the injectable version.Viking Therapeutics (VKTX) remains one of the few clinical-stage biotechs making meaningful progress in obesity drug development. The company is developing VK2735, an investigational novel dual GLP-1 and GIP receptor agonist (RA), in multiple clinical studies as ...